TWI889805B - 器官損傷的預防和治療 - Google Patents

器官損傷的預防和治療

Info

Publication number
TWI889805B
TWI889805B TW110113545A TW110113545A TWI889805B TW I889805 B TWI889805 B TW I889805B TW 110113545 A TW110113545 A TW 110113545A TW 110113545 A TW110113545 A TW 110113545A TW I889805 B TWI889805 B TW I889805B
Authority
TW
Taiwan
Prior art keywords
infection
damage
compound
lung
respiratory
Prior art date
Application number
TW110113545A
Other languages
English (en)
Chinese (zh)
Other versions
TW202143995A (zh
Inventor
麥靖邦
馬法書
肖東
邁克 溥
漢斯 費
Original Assignee
大陸商睿諾醫療科技(上海)有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 大陸商睿諾醫療科技(上海)有限公司 filed Critical 大陸商睿諾醫療科技(上海)有限公司
Publication of TW202143995A publication Critical patent/TW202143995A/zh
Application granted granted Critical
Publication of TWI889805B publication Critical patent/TWI889805B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
TW110113545A 2020-04-15 2021-04-15 器官損傷的預防和治療 TWI889805B (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
WOPCT/CN2020/084820 2020-04-15
CN2020084820 2020-04-15
WOPCT/CN2021/081574 2021-03-18
CN2021081574 2021-03-18

Publications (2)

Publication Number Publication Date
TW202143995A TW202143995A (zh) 2021-12-01
TWI889805B true TWI889805B (zh) 2025-07-11

Family

ID=78085285

Family Applications (1)

Application Number Title Priority Date Filing Date
TW110113545A TWI889805B (zh) 2020-04-15 2021-04-15 器官損傷的預防和治療

Country Status (9)

Country Link
US (1) US12465629B2 (cg-RX-API-DMAC7.html)
EP (1) EP4135743A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023521161A (cg-RX-API-DMAC7.html)
KR (1) KR20230002589A (cg-RX-API-DMAC7.html)
CN (2) CN114245744A (cg-RX-API-DMAC7.html)
AU (1) AU2021256222A1 (cg-RX-API-DMAC7.html)
CA (1) CA3174545A1 (cg-RX-API-DMAC7.html)
TW (1) TWI889805B (cg-RX-API-DMAC7.html)
WO (1) WO2021209003A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3172535A1 (en) 2020-03-26 2021-09-30 Ching-Pong Mak Cyclophilin inhibitors and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103249424A (zh) * 2010-12-03 2013-08-14 美国科技环球有限公司 用于治疗和预防病毒感染的新型环孢菌素衍生物
WO2019016572A1 (en) * 2017-07-21 2019-01-24 Cypralis Ltd CICLOSPORINE ANALOGUES AND USES THEREOF

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0194972B1 (en) 1985-03-11 1992-07-29 Sandoz Ag Novel cyclosporins
FI111730B (fi) 1990-11-02 2003-09-15 Novartis Ag Menetelmä ei-immunosuppressiivisen syklosporiinin valmistamiseksi
JPH08298986A (ja) * 1995-04-28 1996-11-19 Asahi Chem Ind Co Ltd ホスホリパーゼa2酵素
KR970064620A (ko) 1996-03-05 1997-10-13 임성기 사이클로스포린-함유 외용약제 조성물
ATE254630T1 (de) 1998-06-12 2003-12-15 Chem Ag C Cyclosporine
CN101068829B (zh) 2004-10-01 2012-05-30 西尼克斯公司 用于治疗和预防丙型肝炎病毒感染的3-醚和3-硫醚取代的环孢菌素衍生物
PT1802650E (pt) * 2004-10-01 2011-12-30 Scynexis Inc Derivados da ciclosporina 3-éter e 3-tioéter substituída para o tratamento e prevenção da infecção de hepatite c
WO2007041632A2 (en) * 2005-09-30 2007-04-12 Scynexis, Inc. Methods and pharmaceutical compositions for the treatment and prevention of hepatitis c infection
BRPI0708424A2 (pt) 2006-03-02 2011-05-31 Alexion Pharma Inc prolongamento da sobreviência de uma aloenxerto por inibição da atividade do complemento
CA2652662C (en) * 2006-05-19 2015-11-03 Scynexis, Inc. Methods for the treatment and prevention of ocular disorders
WO2008143996A1 (en) 2007-05-18 2008-11-27 Scynexis, Inc. New chemical processes
US8536114B2 (en) 2008-12-31 2013-09-17 Scynexis, Inc. Macrocycles
US9217015B2 (en) 2010-07-16 2015-12-22 S&T Global Inc. Cyclosporin derivatives for the treatment and prevention of a viral infection
GB201217560D0 (en) 2012-10-02 2012-11-14 Mitopharm Ltd Novel cyclic depsipeptide compounds and their uses
TW201639873A (zh) 2015-01-08 2016-11-16 歐樂根公司 Mebmt側鏈已環化之環孢菌素衍生物
CN105983095B (zh) * 2015-02-15 2019-09-13 艾棣维欣(苏州)生物制药有限公司 一种呼吸道合胞体病毒疫苗及其制备方法与应用
CN106902346A (zh) 2015-12-23 2017-06-30 中美华世通生物医药科技(武汉)有限公司 药物组合物及其制药用途
CN106902347A (zh) * 2015-12-23 2017-06-30 中美华世通生物医药科技(武汉)有限公司 亲环孢素抑制剂的用途
CN111449050A (zh) 2019-01-20 2020-07-28 睿诺医疗科技(上海)有限公司 环孢菌素类似物及其用途
CN116870135A (zh) * 2019-10-12 2023-10-13 睿诺医疗科技(上海)有限公司 肾毒素诱发的肾损伤的治疗和预防
CA3172535A1 (en) 2020-03-26 2021-09-30 Ching-Pong Mak Cyclophilin inhibitors and uses thereof
WO2021190603A1 (en) 2020-03-26 2021-09-30 Farsight Medical Technology (Shanghai) Co., Ltd. Cyclophilin inhibitors and uses thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103249424A (zh) * 2010-12-03 2013-08-14 美国科技环球有限公司 用于治疗和预防病毒感染的新型环孢菌素衍生物
WO2019016572A1 (en) * 2017-07-21 2019-01-24 Cypralis Ltd CICLOSPORINE ANALOGUES AND USES THEREOF

Also Published As

Publication number Publication date
TW202143995A (zh) 2021-12-01
CA3174545A1 (en) 2021-10-21
CN113694177B (zh) 2022-06-17
AU2021256222A1 (en) 2022-10-06
EP4135743A4 (en) 2024-05-22
CN113694177A (zh) 2021-11-26
US20230181680A1 (en) 2023-06-15
WO2021209003A1 (en) 2021-10-21
KR20230002589A (ko) 2023-01-05
EP4135743A1 (en) 2023-02-22
US12465629B2 (en) 2025-11-11
CN114245744A (zh) 2022-03-25
JP2023521161A (ja) 2023-05-23

Similar Documents

Publication Publication Date Title
CN108366981A (zh) 用于治疗与间质性肺病相关的咳嗽的甲磺司特
CN113694177B (zh) 器官损伤的预防和治疗
KR20200010164A (ko) 신규한 글루타미닐 고리화효소 억제제 및 다양한 질환의 치료에서의 이의 용도
JP7854206B2 (ja) 肺線維症の予防または治療用の薬学製剤
WO2012026928A1 (en) Use of glycyrrhetinic acid, glycyrrhizic acid and related compounds for prevention and/or treatment of pulmonary fibrosis
CN114432317A (zh) 吡咯并嘧啶类化合物的用途
EA032116B1 (ru) Новое применение n,n-бис-2-меркаптоэтил-изофталамида
CN112972440B (zh) 麝香酮在制备防治抑郁症的药物中的用途
JP2018127489A (ja) 禁煙のためのβ−アドレナリン作動性インバースアゴニストの使用
KR20180065224A (ko) 폐섬유증의 치료 또는 완화용 약학 조성물
US20170216298A1 (en) Beta2-ADRENOCEPTOR AGONIST FOR THE TREATMENT OF COUGH
WO2017084631A9 (zh) 预防或治疗脂肪胰、改善脂肪胰引起的胰病变、糖尿病或其他相关病症之组合物及方法
US20200368158A1 (en) Inhaled preparation of isoglycyrrhizic acid or salt thereof, and use in preparing drugs for treating respiratory system diseases
RU2451507C2 (ru) Лекарственное средство для лечения хронического обструктивного заболевания легких
CN111000847A (zh) 一种治疗肺纤维化的药物制剂及其用途
AU2010322066A1 (en) Treatment of acute exacerbation of asthma and reduction of likelihood of hospitalization of patients suffering therefrom
CN113559100B (zh) 一种治疗肺损伤的组合物及其应用
CN106692976B (zh) P-糖蛋白抑制剂Gelucire44/14作为经口服的盐酸小檗碱吸收促进剂的应用
JP2021502952A (ja) 間質性膀胱炎の処置方法
WO2025020917A1 (zh) 用于治疗脏器纤维化相关疾病的药物组合物和方法
RU2043765C1 (ru) Способ лечения хронических неспецифических заболеваний легких
Sharma et al. Current and Future Prospects in the Treatment of Chronic Obstructive Pulmonary Disorders
KR20240168338A (ko) 호흡기 질환 치료제
Dal Negro et al. Use of aerosols in bronchiectasis patients
US20120295982A1 (en) Treating human male copd patients with oral bedoradrine